The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with ...

Findings from the phase III PATINA trial, presented at the San Antonio Breast Cancer Symposium, showed that adding the CDK4/6 inhibitor palbociclib (Ibrance) to current standard-of-care therapy ...

The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica's FDA 510 (k)-cleared DiviTum TKa assay. Patients were randomized to receive either targeted therapy ...

Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...

Palbociclib plus endocrine therapy did not improve overall survival in premenopausal patients with metastatic breast cancer. The regimen did improve progression-free survival compared with ...

At the recent San Antonio Breast Cancer Symposium, two studies stood out to Norah L. Henry, MD, both offering important insights for clinical practice. The first, the PADMA trial, compared endocrine ...

Please provide your email address to receive an email when new articles are posted on . The combination conferred a clinical benefit rate of 97%. Nearly three-quarters of patients achieved objective ...

Santiago Escrivá, Medical Oncologist at the Vall d’Hebron University Hospital (HUVH) and Clinical Investigator of VHIO’s Breast Cancer Group. Results from an international Phase IIa study point to the ...

Credit: ScienceSource. The objective response rate was 73%, and the clinical benefit rate was 97%. Anastrozole plus palbociclib, trastuzumab, and pertuzumab may provide a chemotherapy-free frontline ...